Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 7, 2016; 22(1): 349-360
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.349
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.349
Figure 4 Serial liver biopsies assessed before and after 1 years’ open label therapy with (A) lamivudine and (B) lamivudine and zidovudine showing a significant reduction in necroinflammatory activity, bile duct injury, and improvement in ductopenia for subjects receiving lamivudine and zidovudine therapy.
With permission from Mason et al[9].
- Citation: Lytvyak E, Montano-Loza AJ, Mason AL. Combination antiretroviral studies for patients with primary biliary cirrhosis. World J Gastroenterol 2016; 22(1): 349-360
- URL: https://www.wjgnet.com/1007-9327/full/v22/i1/349.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i1.349